How complicated skin and soft tissue infections are treated in Italy: economic evaluation of inpatient intravenous antibiotic treatment in seven hospitals

References

• Cohen J, Powderly WG. Infectious Diseases2nd edn. Mosby, New YorkNY 2004
   Google Scholar
• Sax H, Hugonnet S, Harbarth S, et al. Variation in nosocomial infection prevalence according to patient care setting: a hospital-wide survey. Journal of Hospital Infection 2001; 48: 27–32
   Google Scholar
• Porretta A, Giuliani L, Vegni FE, et al. Prevalence and patterns of antibiotic prescribing in Italian hospitals. Infection 2003; 31((Suppl 2))16–21
   Google Scholar
• Gruppo Italiano di Studio sulle Infezioni gravi (GISIG). Infezioni in Terapia Intensiva. Ippolito Edizioni, MilanItaly 1999
   Google Scholar
• Food and Drug Administration. Guidance for Industry. Uncomplicated and complicated skin and skin structure infections—developing antimicrobial drugs for treatment. FDA, 1998. http://www.fda.gov/cder/guidance/2566dft.pdf[accessed 10 November 2007]
   Google Scholar
• Nichols RL. Optimal treatment of complicated skin and skin structure infections. Journal of Antimicrobial Chemotherapy 1999; 44: 19–23
   PubMed Web of Science ®Google Scholar
• Wilson SE. Clinical trial results with linezolid, an oxazolidinone, in the treatment of soft tissue and postoperative gram-positive infections. Surgical Infections 2001; 2: 25–35
   PubMedGoogle Scholar
• Kirby JT, Mutnick AH, Jones RN, et al. Geographic variations in garenoxacin (BMS284756) activity tested against pathogens associated with skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program 2000. Diagnostic Microbiology and Infectious Disease 2002; 43: 303–309
   PubMed Web of Science ®Google Scholar
• Noskin GA. Methicillin-resistant. Staphylococcus aureus and vancomycin-resistant enterococci: emerging problems and new prospects for management. Annals of the Academy of Medicine, Singapore 2001; 30: 320–331
   Google Scholar
• European Antimicrobial Resistance Surveillance System. Annual Report 2004. EARSS, BilthovenThe Netherlands 2004
   Google Scholar
• Jones ME, Karlowsky JA, Draghi DC, et al. Epidemiology and antibiotic susceptibility of bacteria causing skin and soft tissue infections in the USA and Europe: a guide to appropriate antimicrobial therapy. International Journal of Antimicrobial Agents 2003; 22: 406–419
   PubMed Web of Science ®Google Scholar
• Graffunder EM, Venezia RA. Risk factors associated with nosocomial methicillin-resistant. Staphylococcus aureus (MRSA) infection including previous use of antimicrobials. Journal of Antimicrobial Chemotherapy 2002; 49: 999–1005
   Google Scholar
• Lodise TP, McKinnon PS, Rybak M. Prediction model to identify patients with Staphylococcus aureus bacteremia at risk for methicillin resistance. Infection Control and Hospital Epidemiology 2003; 24: 655–661
   Google Scholar
• Lucet JC, Chevret S, Durand-Zaleski I, et al. Prevalence and risk factors for carriage of methicillin-resistant. Staphylococcus aureus at admission to the intensive care unit: results of a multicenter study. Archives of Internal Medicine 2003; 163: 181–188
   Google Scholar
• Solomkin JS, Bjornson HS, Cainzos M, et al. A consensus statement on empiric therapy for suspected gram-positive infections in surgical patients. American Journal of Surgery 2004; 187: 134–145
   PubMed Web of Science ®Google Scholar
• Archer GL. Staphylococcus aureus: a well-armed pathogen. Clinical Infectious Diseases 1998; 26: 1179–1181
   PubMed Web of Science ®Google Scholar
• Diekema DJ, Pfaller MA, Schmitz FJ, et al. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific Region for the SENTRY Antimicrobial Surveillance Program, 1997–1999. Clinical Infectious Diseases 2001; 32((Suppl 2))S114–S132
   Google Scholar
• Rice LB. Antimicrobial resistance in gram-positive bacteria. American Journal of Infection Control 2006; 34((5 Suppl 1): S11–S19; discussion)S64–S73
   Google Scholar
• De Robertis E, Viscidi D, Servillo G, et al. Use of quinupristin/dalfopristin in a critical patient with a methicillin-resistant. Staphylococcus aureus infection. Minerva Anestesiologica 2004; 70: 747–749; 749–751
   Google Scholar
• Weigelt J, Itani K, Stevens D, et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrobial Agents and Chemotherapy 2005; 49: 2260–2266
   PubMed Web of Science ®Google Scholar
• Arbeit RD, Maki D, Tally FP, et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clinical Infectious Diseases 2004; 38: 1673–1681
   PubMed Web of Science ®Google Scholar
• Chen YY, Chou YC, Chou P. Impact of nosocomial infection on cost of illness and length of stay in intensive care units. Infection Control and Hospital Epidemiology 2005; 26: 281–287
   PubMed Web of Science ®Google Scholar
• Horan T, Saint S, Chenoweth C, et al. The role of economic evaluation in infection control. American Journal of Infection Control 2001; 29: 338–344
   Google Scholar
• Haley RW. Cost–benefit analysis of infection control programs. In:. Hospital Infections, JV Bennett, PS Brachman. Lippincott-Raven, PhiladelphiaPA 1998; 249–267., Editors., 4th edn.
   Google Scholar
• Jarvis WR. Selected aspects of the socioeconomic impact of nosocomial infections: morbidity, mortality, cost, and prevention. Infection Control and Hospital Epidemiology 1996; 17: 552–557
   PubMed Web of Science ®Google Scholar
• Anon R. New classification of physical status. Anesthesiology 1963; 24: 111
   Google Scholar
• Tarricone R. Cost-of-illness analysis. What room in health economics?. Health Policy 2006; 77: 51–63
   PubMed Web of Science ®Google Scholar
• Heerey A, McGowan B, Ryan M, et al. Microcosting versus DRGs in the provision of cost estimates for use in pharmacoeconomic evaluation. Expert Reviews of Pharmacoeconomics & Outcomes Research 2002; 2: 29–33
   PubMedGoogle Scholar
• Wolff N. Measuring costs: what is counted and who is accountable?. Disease Management and Clinical Outcomes 1998; 1: 114–128
   Google Scholar
• Shuman LJ, Wolfe H. The origins of hospital microcosting. Journal of the Society for Health Systems 1992; 3: 61–74
   Google Scholar
• Agenzia Italiana del Farmaco (AIFA). Italian Pharmaceutical Formulary 2005. http://www.agenziafarmaco.it./wscs_render_attachment_by_id/111.20096.1133834931742d4a5.pdf[accessed 10 November 2007]
   Google Scholar
• Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the Economic Evaluation of Health Care Programmes, 3rd edn. Oxford Medical Publications, New YorkNY 1997.
   Google Scholar
• Rutten-Van Mölken MPMH, Van Doorslaer EKA, Van Vliet RCJA. Statistical analysis of cost outcomes in a randomized controlled clinical trial. Health Economics 1994; 3: 333–345
   PubMed Web of Science ®Google Scholar
• Fung HB, Chang JY, Kuczynski S. A practical guide to the treatment of complicated skin and soft tissue infections. Drugs 2003; 63: 1459–1480
   PubMed Web of Science ®Google Scholar
• Harrington C, Zagari MJ, Corea J, et al. A cost analysis of diabetic lower-extremity ulcers. Diabetes Care 2000; 23: 1333–1338
   PubMed Web of Science ®Google Scholar
• Persson U, Willis M, Odegaard K, et al. The cost-effectiveness of treating diabetic lower extremity ulcers with becaplermin (Regranex): a core model with an application using Swedish cost data. Value in Health 2000; 3((Suppl 1))39–46
   Google Scholar
• Graves N, Weinhold D, Tong E, et al. Effect of healthcare-acquired infection on length of hospital stay and cost. Infection Control and Hospital Epidemiology 2007; 28: 280–292
   PubMed Web of Science ®Google Scholar
• Stone PW, Braccia D, Larson E. Systematic review of economic analyses of health care-associated infections. American Journal of Infection Control 2005; 33: 501–509
   PubMed Web of Science ®Google Scholar
• Davey PG. Cost-effectiveness of antibiotic prophylaxis of wound infection. Journal of Chemotherapy 1994; 6((Suppl 2))29–33
   Google Scholar
• Tarricone R, Torbica A. Hospital cost of central venous catheter-associated blood stream infection (BSI) and cost-effectiveness of closed vs open infusion system. The case of Intensive Care Units in Italy. In: Eighth Congress of the International Federation of Infection Control; 18–21 October 2007; Budapest, Hungary
   Google Scholar